Advertisement
Screener

VERICEL CORPORATION (VCEL) Net Cash Provided by (Used in) Continuing Operations

2.8 / 5 stars · 68/120 Roast Me

VERICEL CORPORATION Net Cash Provided by (Used in) Continuing Operations

VERICEL CORPORATION (VCEL) reported Net Cash Provided by (Used in) Continuing Operations of -$8.58 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-26.

Discontinued › Cash Flow › Other Cash Flow Items

us-gaap:NetCashProvidedByUsedInContinuingOperations · last filed 2019-02-26

  • VERICEL CORPORATION net cash provided by (used in) continuing operations for the quarter ending 2017-03-31 was -$3.13M.
  • VERICEL CORPORATION net cash provided by (used in) continuing operations for the quarter ending 2016-12-31 was $14.10M.
  • VERICEL CORPORATION net cash provided by (used in) continuing operations for the quarter ending 2016-09-30 was -$955.00K.
  • VERICEL CORPORATION net cash provided by (used in) continuing operations for the quarter ending 2016-06-30 was -$3.71M.
  • VERICEL CORPORATION net cash provided by (used in) continuing operations for fiscal 2018 was -$8.58M, a 320.80% decline from fiscal 2017.
  • VERICEL CORPORATION net cash provided by (used in) continuing operations for fiscal 2017 was $3.88M, a 53.75% decline from fiscal 2016.
  • VERICEL CORPORATION net cash provided by (used in) continuing operations for fiscal 2016 was $8.40M.
  • VERICEL CORPORATION net cash provided by (used in) continuing operations for fiscal 2015 was -$15.76M, a 170.73% decline from fiscal 2014.
Period endNet Cash Provided by (Used in) Continuing Operations 3 monthNet Cash Provided by (Used in) Continuing Operations 6 monthNet Cash Provided by (Used in) Continuing Operations 9 monthNet Cash Provided by (Used in) Continuing Operations 12 monthNet Cash Provided by (Used in) Continuing Operations 270 monthNet Cash Provided by (Used in) Continuing Operations 273 monthNet Cash Provided by (Used in) Continuing Operations 276 monthNet Cash Provided by (Used in) Continuing Operations 279 monthNet Cash Provided by (Used in) Continuing Operations 282 monthNet Cash Provided by (Used in) Continuing Operations 285 monthNet Cash Provided by (Used in) Continuing Operations 288 monthNet Cash Provided by (Used in) Continuing Operations 291 monthNet Cash Provided by (Used in) Continuing Operations 294 monthNet Cash Provided by (Used in) Continuing Operations 297 monthNet Cash Provided by (Used in) Continuing Operations 300 month
2018-12-31-$8.58M
10-K · filed 2019-02-26
2017-12-31$3.88M
10-K · filed 2019-02-26
2017-03-31-$3.13M
10-Q · filed 2017-05-10
$10.97M
derived: sum of 2 quarters · filed 2019-02-26
$10.01M
derived: sum of 3 quarters · filed 2019-02-26
$6.30M
derived: sum of 4 quarters · filed 2019-02-26
2016-12-31$14.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26
$13.14M
derived: sum of 2 quarters · filed 2019-02-26
$9.43M
derived: sum of 3 quarters · filed 2019-02-26
$8.40M
10-K · filed 2019-02-26
2016-09-30-$955.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07
-$4.66M
derived: sum of 2 quarters · filed 2016-11-07
-$5.70M
10-Q · filed 2016-11-07
-$9.84M
derived: sum of 4 quarters · filed 2018-03-05
2016-06-30-$3.71M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08
-$4.75M
10-Q · filed 2016-08-08
-$8.89M
derived: sum of 3 quarters · filed 2018-03-05
-$10.38M
derived: sum of 4 quarters · filed 2018-03-05
2016-03-31-$1.04M
10-Q · filed 2017-05-10
-$5.18M
derived: sum of 2 quarters · filed 2018-03-05
-$6.67M
derived: sum of 3 quarters · filed 2018-03-05
-$12.36M
derived: sum of 4 quarters · filed 2018-03-05
2015-12-31-$4.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05
-$5.64M
derived: sum of 2 quarters · filed 2018-03-05
-$11.32M
derived: sum of 3 quarters · filed 2018-03-05
-$15.76M
10-K · filed 2018-03-05
2015-09-30-$1.49M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07
-$7.18M
derived: sum of 2 quarters · filed 2016-11-07
-$11.62M
10-Q · filed 2016-11-07
-$18.85M
derived: sum of 4 quarters · filed 2017-03-13
2015-06-30-$5.68M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08
-$10.13M
10-Q · filed 2016-08-08
-$17.36M
derived: sum of 3 quarters · filed 2017-03-13
$12.96M
derived: sum of 4 quarters · filed 2017-03-13
2015-03-31-$4.44M
10-Q · filed 2016-05-10
-$11.68M
derived: sum of 2 quarters · filed 2017-03-13
$18.64M
derived: sum of 3 quarters · filed 2017-03-13
$17.07M
derived: sum of 4 quarters · filed 2017-03-13
2014-12-31-$7.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13
$23.08M
derived: sum of 2 quarters · filed 2017-03-13
$21.51M
derived: sum of 3 quarters · filed 2017-03-13
$22.28M
10-K · filed 2017-03-13
2014-09-30$30.32M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13
$28.74M
derived: sum of 2 quarters · filed 2015-11-13
$29.52M
10-Q · filed 2015-11-13
$26.76M
derived: sum of 4 quarters · filed 2016-03-14
2014-06-30-$1.57M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12
-$796.00K
10-Q · filed 2015-08-12
-$3.55M
derived: sum of 3 quarters · filed 2016-03-14
$2.77M
derived: sum of 4 quarters · filed 2016-03-14
2014-03-31$777.00K
10-Q · filed 2015-05-14
-$1.98M
derived: sum of 2 quarters · filed 2016-03-14
$4.34M
derived: sum of 3 quarters · filed 2016-03-14
-$390.00K
derived: sum of 4 quarters · filed 2016-03-14
$8.84M
10-Q · filed 2014-05-15
2013-12-31-$2.76M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14
$3.56M
derived: sum of 2 quarters · filed 2016-03-14
-$1.17M
derived: sum of 3 quarters · filed 2016-03-14
-$5.58M
10-K · filed 2016-03-14
$8.06M
10-K · filed 2014-03-13
2013-09-30$6.32M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13
$1.59M
derived: sum of 2 quarters · filed 2014-11-13
-$2.82M
10-Q · filed 2014-11-13
-$10.27M
derived: sum of 4 quarters · filed 2015-03-25
$10.82M
10-Q · filed 2013-11-12
2013-06-30-$4.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14
-$9.14M
10-Q · filed 2014-08-14
-$16.59M
derived: sum of 3 quarters · filed 2015-03-25
-$24.17M
derived: sum of 4 quarters · filed 2015-03-25
$4.49M
10-Q · filed 2013-08-07
2013-03-31-$4.41M
10-Q · filed 2014-05-15
-$11.86M
derived: sum of 2 quarters · filed 2015-03-25
-$19.44M
derived: sum of 3 quarters · filed 2015-03-25
-$27.51M
derived: sum of 4 quarters · filed 2015-03-25
$9.23M
10-Q · filed 2013-05-08
2012-12-31-$7.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-25
-$15.03M
derived: sum of 2 quarters · filed 2015-03-25
-$23.09M
derived: sum of 3 quarters · filed 2015-03-25
$8.11M
10-K · filed 2015-03-25
$13.64M
10-K · filed 2013-03-18
2012-09-30-$7.58M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12
-$15.64M
derived: sum of 2 quarters · filed 2013-11-12
$15.56M
10-Q · filed 2013-11-12
$9.14M
derived: sum of 4 quarters · filed 2014-03-13
$21.09M
10-Q · filed 2012-11-08
2012-06-30-$8.07M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07
$23.14M
10-Q · filed 2013-08-07
$16.72M
derived: sum of 3 quarters · filed 2014-03-13
$10.14M
derived: sum of 4 quarters · filed 2014-03-13
$28.67M
10-Q · filed 2012-08-07
2012-03-31$31.20M
10-Q · filed 2013-05-08
$24.79M
derived: sum of 2 quarters · filed 2014-03-13
$18.21M
derived: sum of 3 quarters · filed 2014-03-13
$12.11M
derived: sum of 4 quarters · filed 2014-03-13
$36.73M
10-Q · filed 2012-05-10
2011-12-31-$6.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13
-$12.99M
derived: sum of 2 quarters · filed 2014-03-13
-$19.09M
derived: sum of 3 quarters · filed 2014-03-13
-$25.72M
10-K · filed 2014-03-13
$5.53M
10-K · filed 2012-03-15
2011-09-30-$6.57M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08
-$12.67M
derived: sum of 2 quarters · filed 2012-11-08
-$19.30M
10-Q · filed 2012-11-08
$11.95M
10-Q · filed 2011-11-08
2011-06-30-$6.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07
-$12.73M
10-Q · filed 2012-08-07
2011-03-31-$6.63M
10-Q · filed 2012-05-10
2010-12-31$17.13M
10-K · filed 2013-03-18
2010-09-30-$273.00K
10-Q · filed 2011-11-08
2010-06-30-$2.88M
10-K · filed 2013-03-18
2009-06-30$508.00K
10-K · filed 2012-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
NOVAVAX INC (NVAX)United States$1.748B-6.26
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Greenland Mines Ltd (GRML)United States$2.362B
Immunocore Holdings plc (IMCR)$1.613B-90.43
Taysha Gene Therapies, Inc. (TSHA)United States$1.564B-14.80